Inhibrx Biosciences, Inc.

Phylaxis Bioscience, LLC

Kyle S Jones

Brendan P Eckelman

John C Timmer

Bryan Becklund

Quinn L Deveraux

Rajay A Pandit

Amir S Razai

Katelyn M Willis

Abrahim Hussain

Lucas Rascon

William Crago

Mike Kaplan

Chelsie Macedo

Angelica N Sanabria

Andrew Hollands

Michael D Kaplan

Milton Ma

Florian Sulzmaier

Jacob Gano

Tony Dung-Ling Yao

Andrew M Eckles

Provided herein are VHH-containing polypeptides that bind OX40. In some embodiments, VHH-containing polypeptides that bind and agonize OX40 are provided. Uses of the VHH-containing polypeptides are also provided.

OX40-binding polypeptides and uses thereof

Provided herein are IgE-binding VHH domains, polypeptides, and proteins, and methods of using such IgE-binding polypeptides and proteins to modulate the biological activity of IgE.

IgE binding proteins and uses thereof

This invention relates generally to molecules that specifically engage OX40, a member of the TNF receptor superfamily (TNFRSF). More specifically this invention relates to multivalent and multispecific molecules that bind at least OX40.

Multivalent and multispecific OX40-binding fusion proteins

The invention relates generally to multispecific polypeptides that bind at least CD3, a second antigen, and a receptor of a T cell, such as a costimulatory receptor or an inhibitory receptor, in which the multispecific polypeptide constructs are able to engage CD3. In some embodiments, the multispecific polypeptide constructs bind a costimulatory receptor and provide costimulatory binding activity. In some embodiments, the multispecific polypeptide constructs bind an inhibitory receptor and block inhibitory activity. In some aspects, the multispecific polypeptides have constrained CD3 binding and bind to or engage CD3 only upon binding to the second antigen, such as a tumor associated antigen. In some embodiments, the multispecific polypeptides contain cleavable linkers that, when cleaved, result in dual effector functions. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.

Multispecific polypeptide constructs containing a constrained CD3 binding domain and a receptor binding region and methods of using the same

This invention relates generally to molecules that specifically engage 41BB, a member of the TNF receptor superfamily (TNFRSF). More specifically, this invention relates to multivalent and multispecific molecules that bind at least 41BB.

Multivalent and multispecific 41BB-binding proteins

Provided herein are VHH-containing polypeptides that bind CD33. Uses of the VHH-containing polypeptides are also provided.

CD33-binding polypeptides and uses thereof

Growing community of inventors

San Marcos, CA, United States of America

Kyle S Jones